Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U8XW
|
|||
| Former ID |
DIB008299
|
|||
| Drug Name |
APX-3330
|
|||
| Synonyms |
AR-03; E-3330; APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics; APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics; E-3330 analogs (cancer/retinopathy), ApeX Therapeutics
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Ocular cancer [ICD-11: 2D00-2D07] | Discontinued in Phase 2 | [2] | ||
| Company |
ApeX Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | AP endonuclease 1 (APEX1) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Base excision repair | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| WikiPathways | Spinal Cord Injury | |||
| TSH signaling pathway | ||||
| Base Excision Repair | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035303) | |||
| REF 3 | Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.